EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity

SeongHo Jo, Gu Jing, Junqin Chen, Guanlan Xu, Anath Shalev iD

Diabetes, Obesity and Metabolism · 2025-04 · 27 (4) · 2223-2231

DOI: 10.1111/dom.16223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.02.2025. Verfasst von SeongHo Jo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Diabetes Center, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birm…. Hauptthemen laut MEDLINE: Obesity, Glucose Intolerance, Adiposity, Carrier Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Glucagon‐like peptide 1 receptor agonists and dual agonists have changed the treatment landscape of obesity and type 2 diabetes (T2D), but significant limitations have emerged due to their gastrointestinal side effects, loss of lean mass, and necessity for ongoing subcutaneous injections. Our objective was, therefore, to test a novel small molecule as a different and potentially better tolerated oral medications to improve obesity‐associated impairment in glucose homeostasis. Materials and Methods High‐fat diet (HFD)‐fed mice or severely obese, leptin‐deficient ob/ob mice were randomly assigned to serve as controls or receive oral TIX100, a novel thioredoxin‐interacting protein (TXNIP) inhibitor just approved by the FDA as an investigational new drug for type 1 diabetes (T1D). The TIX100 effects on glucose intolerance and weight control were then assessed.

Results

TIX100 protected against HFD‐induced glucose intolerance, hyperinsulinemia, and hyperglucagonemia. TIX100 also reduced diet‐induced adiposity resulting in 15% lower weight in treated mice as compared with controls on HFD ( p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityGlucose IntoleranceAdiposityCarrier ProteinsAnimalsDiet, High-FatMiceMaleMice, Inbred C57BLMice, ObeseAdministration, OralBlood GlucoseThioredoxins

Stichwörter der Autor:innen

glucose intolerancelean massleptinobesitythioredoxin‐interacting proteintype 2 diabetes

Substanzen

Carrier ProteinsTxnip protein, mouseBlood GlucoseThioredoxins

Autor:innen und Institutionen

  • Comprehensive Diabetes Center, Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, Alabama, USA.

ORCID-Profile: Anath Shalev

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Jo, S., Jing, G., Chen, J., Xu, G., & Shalev, A. (2025). Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity. Diabetes, Obesity and Metabolism, 27(4), 2223-2231. https://doi.org/10.1111/dom.16223

Vancouver

Jo S, Jing G, Chen J, Xu G, Shalev A. Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity. Diabetes, Obesity and Metabolism. 2025;27(4):2223-2231. doi:10.1111/dom.16223

BibTeX
@article{Jo2025,
  author = {Jo, SeongHo and Jing, Gu and Chen, Junqin and Xu, Guanlan and Shalev, Anath},
  title = {Oral TIX100 protects against obesity‐associated glucose intolerance and diet‐induced adiposity},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {4},
  pages = {2223--2231},
  doi = {10.1111/dom.16223}
}
Kostenlos starten →